Long-term exposure to cigarette smoke (CS) results in alveolar parenchyma destruction due to chronic inflammatory response and the imbalance between oxidants and antioxidants, and proteases and antiproteases. Emphysema is the main symptom of chronic obstructive pulmonary disease. Current treatment focuses on relieving respiratory symptoms, and inflammation resolution failure is an important pathophysiological element of the disease. Specialized pro-resolving mediators (SPMs) synthesized endogenously during resolution processes demonstrated beneficial effects in murine models of airway inflammation. Here, we aimed to test the SPM ATRvD1 in a murine model of CS-induced emphysema. AT-RvD1 restored elastic fibers and lung morphology, with reduction in MMP-3, neutrophils, and myeloperoxidase activity and increases in macrophages and IL-10 levels. AT-RvD1 also decreased levels of oxidative stress markers and ROS via upregulation of the Nrf2/Keap1 pathway. Therefore, we suggest that AT-RvD1 causes pro-resolutive action in our murine model of CS-induced emphysema by upregulation of the Nrf2/Keap1 pathway.
Introduction
Chronic obstructive pulmonary disease (COPD) is a common, preventable and treatable disease characterized by persistent respiratory symptoms and airflow limitation that is due to obstructive bronchiolitis or emphysema, and caused by significant exposure to noxious particles or gases [1] . The occurrence of emphysema in individuals with COPD is associated with a decrease in the quality of life as well as an increase in comorbidities [2] . Although cigarette smoke (CS) is the most common cause of COPD, there are other factors that influence its development, such as environmental exposure to air polluted with wood-burning products, charcoal and biomass [3] , and different degrees of deficiency of alpha-antitrypsin-1 [4] [5] [6] [7] .
CS contains > 4700 compounds, most of which are toxic [8] , and 72 of which are considered carcinogenic [9] , reactive oxygen species (ROS), and other organic substances capable of producing ROS, as phenols and quinine [8] . The World Health Organization (WHO) therefore considers the exposure to CS as a powerful oxidative stimulus and an important risk factor in several diseases. Since 1950, smoking has been recognized as a public health problem [10] . In 2010 there were 384 million recorded cases of COPD, with an overall prevalence of 11.7% in the population [11] . These estimates tend to increase over time, due to increasing tobacco use in developing countries that will put COPD as the third leading cause of death in the world by 2030, if current conditions prevail [12] .
Currently it is believed that emphysema occurs mainly by two imbalances: the imbalance between oxidants and antioxidants, and between proteases and antiproteases. The oxidants present in CS activate inflammatory cells (neutrophils, macrophages and epithelial cells) in the airways. These cells then release proinflammatory mediators, which in cases of prolonged exposure to CS lead to the occurrence of oxidant stimuli on the antioxidant defenses of the lung, instituting a chronic inflammatory process. Once chronic inflammation has been established, the increase of lytic cells in the site as well as of protease-producing cells, results in increased action of proteases on antiproteases and further exacerbates the damage of cellular structures, and therefore of the alveolar septum [13] . Both imbalances lead to deficiencies in the processes of resolution of inflammation and repair, so it would be advantageous to adopt a new therapeutic approach in COPD, the aim of which would focus on the process of resolving inflammation, thereby reducing the rate of progression of inflammatory disease and enzymatic processes [14] . Treatment of patients with COPD currently concentrates on the control of exacerbations using prescriptions of inhaled and systemic bronchodilators, and corticosteroid drugs. These can have multiple adverse effects and there are currently no therapies that reduce the inevitable progression of the disease [15] .
The resolution of inflammation is an active process, rapidly initiated after acute or chronic changes by activating the biosynthesis of specialized proresolving mediators (SPMs) including lipid mediators produced via the lipoxygenase pathway from the omega 3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and which have anti-inflammatory and proresolutive attributes [16] . One of these SPMs, resolvin D1 (RvD1) and its synthetic epimer, aspirin-triggered resolvin D1 (AT-RvD1), have equipotent anti-inflammatory and resolutionary effects [17] , and have demonstrated beneficial effects in different models of airway diseases related to inflammation and resolution failures [18] [19] [20] . In the present study, we describe the reparative, anti-inflammatory and antioxidant effects of AT-RvD1 upon emphysema occurring in mouse lungs. In addition, our results suggest that the overall effects of AT-RvD1 are mediated by the upregulation of the Nrf2/Keap1 pathway.
Materials and methods

Animals and reagents
Eight-week old C57BL/6 male mice (18-22 g) were purchased from the Multidisciplinary Center for Biological Investigation on Laboratory Animal Science (CEMIB-UNICAMP, Campinas, SP, Brazil). Mice were fed with Purina Chow (Nuvilab, Curitiba, PR, Brazil) and had unrestricted access to water and food in a controlled environment, maintained at a temperature of 18-22°C, 50-70% relative humidity, and a 12 h light/dark cycle. All procedures were performed in accordance with conventional guidelines for experimentation with animals, and the local committee approved the experimental protocol (006/16). All reagents and chemicals were purchased from Sigma (Sigma-Aldrich, St. Louis, MO, USA), unless otherwise specified.
Cigarette smoke exposure
Mice were divided into 4 groups. The first group was exposed to ambient air ("sham-smoked") for 120 days (CTR group, n = 9). The second group was exposed to CS for 60 days (CS group, n = 5). The final two groups were exposed to CS for the first 60 days and then to ambient air for the next 60 days, during which they received treatment with AT-RvD1 (CSr + AT-RvD1 group, n = 10) or vehicle only (CSr group, n = 5). This model characterizes post-treatment, since at 60 days the animals already had emphysema, as was described by Valenca et al. in 2004 [21] . Mice from the CS group were exposed to 12 commercial filtered cigarettes per day (4 cigarettes in the morning, 4 cigarettes at noon and 4 cigarettes in the afternoon) using a smoking chamber. To summarize the method used: the animals were placed in an inhalation chamber (40 cm long, 30 cm wide, 25 cm high) inside an exhaustion chapel. A cigarette was coupled to a plastic 60 mL syringe so that puffs could be drawn in and subsequently expelled into the exposure camber. Smoke (1 L) from 1 cigarette was aspirated with this syringe, and then each puff was immediately injected into the chamber. Animals were maintained in this smoke-air condition ( ± 3%) for 6 min. The cover was then removed from the inhalation chamber, and the smoke was evacuated within 1 min by turning on the exhaust fan of the chapel. Each cigarette produces 300 mg/m 3 total particulate matter in the chamber, which is measured by weighing the material collected on Pallflex filters (Pall Corporation, New York, NY, USA). Carboxyhemoglobin percentage levels were measured to confirm that the treatment was not toxic [21] . Experimental design was repeated twice.
Treatment with AT-RvD1
The synthetic epimer of RvD1, AT-RvD1, was chosen for our study because of its effects being equipotent to RvD1, but also because of its resistance to oxido-degradation, which has a longer bioactivity time than that of RvD1 [17] . To study the therapeutic effects of AT-RvD1 on pulmonary emphysema, mice from the CSr + AT-RvD1 group were treated with 500 ng AT-RvD1 (17(R)-RvD1, Cayman Chemical, Ann Arbor, MI, USA) injected into the tail vein, from day 61 to day 120 (8 weeks), twice a week as proposed by Siao et al. [22] . The AT-RvD1 was prepared from a commercial solution containing 25 μg AT-RvD1 in 250 μL ethanol. Each mouse was injected with 5 μL commercial solution of AT-RvD1 and 95 μL saline solution. The CSr group was treated with vehicle solution (10 μL ethanol in 90 μL saline solution) using the same method as the CSr + AT-RvD1 group.
Bronchoalveolar lavage and lung homogenates
24 h after day 120, the animals were euthanized by cervical displacement. Bronchoalveolar lavage (BAL) was performed on the right lung of all animals in each group. To summarize the methodology: a cannula was inserted into the trachea, the airspaces were washed three times with buffered saline solution (500 μL at 4°C), and the flow-through (final volume 1.2-1.5 mL) was maintained on ice. The BAL fluid was then centrifuged, and the supernatant was collected and stored at −20°C for subsequent analysis via enzyme-linked immunosorbent assay (ELISA). The pellet was re-suspended in 250 μL buffered saline solution and the total number of cells was determined using a Neubauer chamber. Differential cell counts were performed on cytospin preparations. At least 100 cells were counted per BAL fluid sample, using standard morphologic criteria. The BAL sample was also assessed by quantification of reactive oxygen species (ROS) and microparticles (MP). The right lungs of all animals were removed and homogenized in 1.0 mL lysis buffer and centrifuged at 210g for 10 min, and the supernatants were collected for biochemical analyses and Western blotting. The lysis buffer consisted of 1 tablet of protease inhibitor, 0.1% triton x-100, in 100 mL phosphate buffer. The total protein in the samples (both tissues and BAL samples) was determined using the Bradford method.
Tissue processing and morphometry
The right ventricles of all the mice were perfused with saline to remove the blood. Next, the left lungs of all animals were inflated with 10% phosphate buffered formalin (pH 7.2) at 25 cm H 2 O pressure for 2 min and were then ligated and removed. The inflated lungs were fixed for 48 h prior to being embedded in paraffin. Sagittal, serial 4 μm-sections of the lungs were stained with hematoxylin and eosin (H&E), and orcein for histological analyses. To obtain uniform and proportionate lung samples, 10 fields (5 non-overlapping fields in 2 sections; ×40 objective lens) were analyzed in the upper, middle, and base of the lung using a video microscope (Leica Mikrosysteme Vertrieb GmbH Mikroskopie und Histologie, Wetzlar, Germany). Air-space enlargement (emphysema) was quantified based on the mean linear intercept length of the distal air spaces (Lm) in 10 randomly chosen fields of tissue sections per lung sample [23] . The volume density of the alveolar septa (Vv[alveolar septa]) and the volume density of elastic fibers (Vv[elastic fibers]) were estimated by counting the number of structures that were intersected by the test system (partial points, Pp) considering total points (Tp) in 10 randomly chosen fields per lung sample [24] . All quantifications were performed by an investigator who did not have access to the identity of the histological sections.
Western blotting
Protein sample (30 μg) was resolved by SDS-PAGE and electrotransferred to PVDF membranes. Primary antibodies against matrix S.V. Posso et al.
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metalloproteinase (MMP-3, sc-6839), tissue inhibitor of metalloproteinase 1 (TIMP-1, sc-5538), Kelch-like ECH-associated protein 1 (Keap1, sc-33569) and heme oxygenase 1 (HO-1, sc-1796) were purchased from Santa Cruz (Santa Cruz Biotechnology Inc, Dallas, TX, USA). Primary antibodies against nuclear factor (erythroid-derived 2)-like 2 (Nrf2, SAB25021713) and beta-actin (β-actin, A5441) were purchased from Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO, USA). Protein detection was performed with the appropriate horseradish peroxidase-conjugated secondary antibody/ECL detection system using Amersham ECL prime western blotting reagent (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA) and the chemiluminescence imaging system ImageQuant LAS 4000 (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA). Levels of proteins in the membranes were quantified by densitometry (the ImageJ program from National Institutes of Health).
Enzyme-linked immunosorbent assay (ELISA)
Interleukin-10 (IL-10) was quantified in BAL samples using a specific enzyme-linked immunosorbent assay with a rat anti-mouse monoclonal antibody and a detection limit of 2000 pg/mL, according to the manufacturer's instructions (R&D Systems, Minneapolis, MN, USA). Mouse recombinant IL-10 standard was used in this assay.
Myeloperoxidase activity
Myeloperoxidase (MPO) activity in BAL fluid was measured with hexadecyltrimethylammonium bromide (HTAB), tetramethylbenzidine (TMB) and hydrogen peroxide. Initially, 100 μL sample was centrifuged with 900 μL HTAB at 14,000g for 15 min. Supernatant sample (75 μL) was then incubated with 5 μL TMB for 5 min at 37°C. Hydrogen peroxide (50 μL) was then added, and the mixture was incubated for 10 min at 37°C. Finally, 125 μL sodium acetate buffer was added. The reaction was measured with a microplate reader at 630 nm [25] .
Microparticles
To obtain the MP present in the BAL fluid, cell suspensions were subjected to 2 consecutive rounds of centrifugation at 400g, to remove whole cell contamination. The supernatants of this initial centrifugation step were subjected to ultracentrifugation at 100,000g for 4 h at 4°C. The pellets enriched in MP were re-suspended in Annexin V binding buffer, which labels MP with Annexin V, in order to determine the precise number of MP per μL. Furthermore, MP were re-suspended in FACS buffer for labeling cell surface marker antibodies: F4/80 to determine the number of MP derived from macrophages, and Ly6g to determine the number of MP derived from neutrophils. The assessments of MP were then performed in an Accuri C6TM flow cytometer (BD Biosciences, San Jose, CA, USA) through the evaluation of annexin-V, F4/80 or Ly6g positive events. To delimitate the area containing MP, a 1 μm bead was used. A bead of 2 μm in a known concentration was also used to estimate the precise amount of MP.
Redox markers
Reactive oxygen species (ROS) detection was performed in BAL cells Representative images of lung parenchyma from ×20 (a, c, e and g) and ×40 (b, d, f and h) magnification showing alterations in its morphology by enlargement of the alveolar spaces in the CS and CSr groups, which is restored in the CSr + ATRvD1 group. Lung histology was confirmed by two independent experiments. g) Lm was quantified in 10 randomly chosen fields of tissue sections per lung samples, stained with H&E (×40 magnification). Data are shown as the mean ± SEM. *p < 0.05 when compared with the control group. # p < 0.05 when compared with the CS and CSr group. Control group, n = 9. CS group, n = 5. CSr group, n = 5. CSr + AT-RvD1 n = 10.
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following the adapted nitroblue tetrazolium chloride protocol [26] . To summarize, ROS produced by cells reacted with NBT to generate blue formazan. The optical density was read in a microplate reader at 630 nm. BAL cells were also used for detection of intracellular ROS by probe 2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA) following the manufacturer's instructions (Molecular Probes, Eugene, OR, USA). BAL and probe samples were incubated for 1 h in a 96-well black plate. After 3 washes in phosphate-buffered saline the fluorescence reading was performed on an Envision Multilabel plate reader (Perkin Elmer, Waltham, MA, USA). Fluorescence was monitored for up to 90 min incubation through excitation and emission wavelengths 495 and 530 nm, respectively. The 70th minute of the reading was chosen to represent the results on a graph containing the area under curve (AUC). Lung homogenates were used for biochemical assays. Superoxide dismutase (SOD) activity was assayed by monitoring the inhibition of adrenaline auto-oxidation at 480 nm [27] . Catalase (CAT) activity was measured by the rate of decrease of hydrogen peroxide concentrations, monitored at 240 nm [28] .
Statistical analyses
The values for all measurements in the graphs are expressed as the mean ± standard error of the mean (SEM). All statistical analyses were performed with one-way ANOVA, followed by Bonferroni post hoc test (p < 0.05 was considered statistically significant). GraphPad Prism software was used to perform the statistical analyses (GraphPad Prism version 5.0, San Diego, CA, USA).
Results
AT-RvD1 reduced alveolar enlargement
To confirm our experimental model of emphysema we sampled a group 24 h after 60 days and Lm was measured (CS group). To confirm the progression of our experimental model of emphysema, a separate group of mice was sampled 24 h after 120 days (CSr group) and Lm was again measured. As expected, the CS group ( Fig. 1c and d) showed destruction of alveolar septa, and therefore increases in the Lm compared with the control group (Fig. 1a and b) , which demonstrate preservation of lung parenchyma (p < 0.05). The Lm in the CSr group ( Fig. 1e and f) and the CS group demonstrated no difference to evidence the maintenance of emphysema after stopping CS exposure and mimicking the clinical characteristics of COPD patients. Interestingly, the AT-RvD1 treatment ( Fig. 1g and h ) reduced the Lm (p < 0.05) and restored pulmonary parenchyma to show a similar pattern to that of the control group.
AT-RvD1 restored lung elastic fibers and improved MMP-3/TIMP-1 balance
Elastic fibers are a major component of the extracellular matrix in the alveolar septa, and their degradation leads to loss of pulmonary elastic recoil [29] . Using morphometrical methods, we measured the volume density of elastic fibers in lung sections stained with orcein, over the volume density of the alveolar septa. As evidenced in the microphotographs the elastic fibers, stained brown, were present in lower quantities in the CSr group ( Fig. 2c and d ) compared with the control group (Fig. 2a and b) . Treatment with AT-RvD1 (Fig. 2e and f) restored elastic fibers when compared with the CSr group. Consequently, the ratio (Fig. 2g) between elastic fibers and alveolar septa volume densities was reduced in the CSr group when compared to the control group (p < 0.01), meaning a loss of elastic fibers in the alveolar septa. The AT-RvD1 group presented an increase of this ratio (p < 0.01), reaching the values of the control group.
Matrix metalloproteinases substantially contribute to lung matrix degradation during the evolution of emphysema [30] induced by CS, generating an imbalance of MMPs and TIMPs that is recognized as a hallmark of COPD pathogenesis [13] . To this end, we measured the expression of MMP-3 and TIMP-1 by western blotting of lung homogenate. MMP-3 degrades elastic fibers as well as activating other MMPS [31] . We observed an increase of MMP-3 expression in CSr group (p < 0.07) when compared to the control group, and the treatment with AT-RvD1 reduced it when compared to the CSr group (p < 0.08) (Fig. 3a) . TIMP-1 was increased in both CSr and CSr + AT-RvD1 group when compared to the control group (p < 0.01) (Fig. 3b) .
AT-RvD1 decreased inflammatory markers
RvD1 has demonstrated proresolutive effects in several models of acute and chronic inflammation as stated in the introduction section, and its epimer, AT-RvD1, demonstrates an important effect in our model by decreasing inflammatory markers. The total number of leukocytes (Fig. 4a) Control group, n = 9. CS group, n = 5. CSr group, n = 5. CSr + AT-RvD1, n = 10.
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(p < 0.01). CSR + AT-RvD1 also demonstrated an increase of leukocytes when compared to the control group (p < 0.05). After performing the differential cell counting, it was evident that the increase in total leukocytes in the CSr + AT-RvD1 group was due to the increase in the number of macrophages (p < 0.001) (Fig. 4b ) since neutrophils had increased in CSr group, compared to the control group (p < 0.001) (Fig. 4c) . Neutrophils returned to basal levels after AT-RvD1 treatment (p < 0.001). The number of lymphocytes did not differ significantly between the groups (Fig. 4d) . The levels of IL-10, a proresolution marker, decreased in the CSr group compared with the control group (p < 0.05) and returned to basal levels compared with the CSr group (p < 0.05) (Fig. 4e) . Finally, the levels of MPO, a marker of neutrophils, matched the respective results of neutrophil numbers, since an increase in MPO was observed in the CSr group when compared to the control group (p < 0.05) and the treatment with AT-RvD1 reduced the MPO when compared to the CSr group (p < 0.05) (Fig. 4f) . 
AT-RvD1 reduced microparticles released from leukocytes
MPs are considered to be inflammatory markers in several diseases, including those related to airway inflammation [32] . After degranulation, activated neutrophils released MP containing opsonin receptors, as well as MPO and elastase [33] . Quantification of MP was performed on BAL samples, and we observed its increase in both CS and CSr groups, compared with the control group (p < 0.001) (Fig. 5a ). The treatment with AT-RvD1 was effective in reducing MP when compared with the CSr group (p < 0.001). The numbers of MPs derived from macrophages and neutrophils were analyzed in the CSr group, and both were found to be increased when compared with the control ones (p < 0.01) (Fig. 5b and c) . Although the MPs derived from macrophages appear to have decreased in the CSr + AT-RvD1 group compared with the CSr group, there was no significant statistical difference between these groups. However, MPs derived from neutrophils showed a decrease in the CSr + AT-RvD1 group, compared with the CSr group (p < 0.05). The figure of dot plots from MPs are presented as Supplemental figure. 
AT-RvD1 reduced oxidative stress
Because the imbalance between oxidants and antioxidants is considered pivotal during the development of emphysema [13] , we evaluated different markers of oxidative stress. Total ROS levels (p < 0.05) and intracellular ROS levels (p < 0.001) in the BAL were higher in the CSr group compared with the control group (Fig. 6a and b, respectively) . Treatment with AT-RvD1 decreased both total and intracellular ROS levels to baseline (p < 0.01). SOD activity (Fig. 6c) was reduced (p < 0.09) in the CSr group when compared to the control group, while CAT activity (Fig. 6d) was increased (p < 0.01) . AT-RvD1 inversely modulated SOD and CAT activities significantly, compared to the CSr group (p < 0.05).
AT-RvD1 upregulated Nrf2/Keap1 pathway
The major protein related to oxidative stress is Nrf2. In normal conditions, Nrf2 is attached to Keap1 in the cytoplasm. In general, 
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International Immunopharmacology 56 (2018) [330] [331] [332] [333] [334] [335] [336] [337] [338] oxidative stimuli activates the disengagement of Nrf2 from Keap1 and translocates it into the nucleus to initiate the transcription of antioxidant enzymes [34] . To evaluate the participation of this pathway in this model of emphysema, we measured the expression ratio of Nrf2 and Keap1 using western blotting. The Nrf2:Keap1 ratio diminished in the CSr group compared with the control group (p < 0.05) (Fig. 7a) , evidencing an increase in the expression of Keap1 to the detriment of the expression of Nrf2. Interestingly, the CSr + AT-RvD1 group demonstrated an important increase in this ratio when compared to the control and CSr groups (p < 0.001). To confirm that AT-RvD1 is able to upregulate the expression of Nrf2, we measured the expression of HO-1 (Fig. 7b) , which is one of the main antioxidant enzymes produced by the activation of Nrf2 [34] . Expression of HO-1 was low in the CSr group compared with the control group (p < 0.05), and it was restored with treatment of AT-RvD1 when compared to the CSr group (p < 0.05).
Discussion
AT-RvD1 has already demonstrated the ability to repair pulmonary parenchyma in a murine model of lung injury caused by bleomycin [20] , and in another model of cigarette smoke-induced emphysema [22] , but the molecular mechanisms of how this repair occurs is still unclear. In this study, we confirmed the ability of AT-RvD1 to repair lung parenchyma after damage caused by long-term CS exposure. We observed improvement of lung parenchyma morphology and decreased alveolar enlargement in AT-RvD1-treated mice. This study is the first to demonstrate the ability of AT-RvD1 to repair elastic fibers in mouse lungs. Elastic fibers are among the most difficult extracellular matrix structures to repair because of their size, molecular complexity and the requirement for numerous helper proteins to facilitate fiber assembly [29] . AT-RvD1 seems play a role in their repair but the molecular mechanisms are still unclear.
The MMPs are a family of enzymes with the ability to degrade components of ECM and they play critical roles in tissue remodeling and wound repair. In the lungs of COPD patients, there is an imbalance between MPPs, which break down connective tissue components, and TIMPs, which counterbalance this action [35] and this imbalance is considered fundamental within the pathogenesis of emphysema [13] . In particular, MMP-3 is known to be expressed by alveolar macrophages [36] , and it has been shown that there is a relationship between increased MMP-3 expression and the prevalence of emphysema quantified by CT in subjects with COPD [37] and that this increase is associated with all COPD sub-types [38] . In murine models of chronic lung inflammation induced by CS, the role of MMP-3 has not been well established. Here, we show that the expression of MMP-3 in the CSr group is increased. MMP-3 degrades multiple ECM proteins in addition to the growth factors and cleavage of cell adhesion molecules that culminate with the activation of other MMPs [39] . Concordantly, the MMP-3 increase in the CSr group could be related to the increase in elastic fiber degradation and the parallel increase in the number of neutrophils in this group. AT-RvD1 has already demonstrated the ability to regulate the expression of MMPs and TIMPs in a murine model of pulmonary fibrosis induced by bleomycin [20] . Here, the expression of MMP-3 in mice treated with AT-RvD1 was diminished, supporting the beneficial effects of this epimer of RvD1 and showing, for first time, its ability to regulate the expression of a member of the MMP family in a model of CS-induced emphysema. Conversely, TIMP-1 performs inhibition of MMPs under normal conditions, but during the establishment of emphysema, it is reduced in parallel to the increased prevalence of MMPs [30] . In the present study, an interesting increase occurred in TIMP-1 expression in both the CSr group and the CSr + AT-RvD1 group, but in the CSr + AT-RvD1 group MMP-3 was reduced, as previously discussed. The increase of TIMP-1 in parallel to the reduction of MMP-3 in the CSr + AT-RvD1 group is a well established balanced process, indicating lower levels of ECM protein degradation, which is reflected in less tissue damage. This result shows that AT-RvD1 downregulates MMP-3 expression but does not alter TIMP-1 expression that remains high beyond 60 days after emphysema is established and after smoking has stopped.
One of the pathological changes observed in patients with COPD is chronic inflammation, with increased numbers of specific inflammatory cell types [14] . Here, we demonstrated that in mice with emphysema there are a high number of neutrophils and this is consistent with the increase in MPO activity. MPO is an antimicrobial system formed in the phagosoma of neutrophils, that when released can attack normal tissue and thus contributes to the pathogenesis of many diseases [40] . Treatment with AT-RvD1 was able to decrease these inflammatory markers, the neutrophil numbers and MPO activity. Recently it was reported in a model of acute pancreatitis associated with lung injury, that RvD1 decreased the MPO activity in the pancreatic and pulmonary tissue [41] . We also observed that treatment with AT-RvD1 increased the total number of cells in BAL due to the increased number of macrophages. This demonstrates that AT-RvD1 favors a microenvironment of pro-resolution of inflammation, since during the normal process of resolution cessation of leukocyte infiltration occurs in parallel to neutrophil death and nonphlogistic infiltration of macrophages [42] .
All eukaryotic cells have the ability to form MP and this formation is mainly stimulated by two mechanisms, cell activation and apoptosis, both of which are involved in inflammatory responses [43] . These mechanisms induce formation of blebs outward from the plasma membrane, with subsequent release after proteolytic cleavage of the cytoskeleton [44] which contains molecules that promote intercellular communication. MP are recognized as inflammatory markers in several diseases, including those related to airway inflammation [32] . Here, we demonstrated for the first time, in a murine model of emphysema, that exposure to CS may lead to an increase in the number of total MP and that AT-RvD1 decreases the presence of those MP, supporting evidence for its role as anti-inflammatory agent. In clinical models of COPD, it has been demonstrated that plasma MP derived from endothelial cells may be a marker of early emphysema [45] . However, the role of MP derived from neutrophils and macrophages has never been reported either in clinical models or in animal models. The present study demonstrated that there is a significant increase in neutrophil-derived MP in mice with emphysema due to CS exposure. It is well known that neutrophil-derived MP contain inflammatory response amplifiers, such as complement receptor 1, myeloperoxidase and neutrophil elastase [33] , with the latter two closely related to tissue injury in emphysema conditions. This supports the results found in the CSr group that showed greater tissue damage, fewer elastic fibers, and higher numbers of neutrophils and MPO activity. The increase in the number of MP derived from neutrophils was countered by a decrease caused by treatment with AT-RvD1, evidencing the ability of AT-RvD1 to downregulate the main inflammatory response: namely, the activation of neutrophils and the ability to promote efferocytosis [46] . Unfortunately we have failed to confirm the origin of these MPs by other tools such as transmission electron microscopy and/or western blotting. Our MP result is related only to the methodology used (Facs) which obviously have some limitations, even though it is a robust method of analysis and extensively used for this purpose. We considered this point as a limitation of our study, which does not invalidate the data obtained.
The imbalance between oxidants and antioxidants leading to oxidative stress is also important within the pathophysiology of COPD, firstly because there is an increase in the levels of ROS since CS is itself a ROS resource, and secondly because of the endogenous ROS produced by the establishment of chronic inflammation (from inflammatory cells) [13] . AT-RvD1 has already demonstrated its ability to reduce ROS levels in different models of inflammation [46, 47] . Here, we observed that AT-RvD1 treatment also decreased the levels of intracellular and extracellular ROS, which is related to its effects on decreasing inflammatory markers. AT-RvD1 also upregulated the activity of SOD, the main antioxidant enzyme that degrades superoxide anion [48] . Interestingly, this increase in SOD activity is associated with a decrease in the total levels of ROS observed in the same group (CSr + AT-RvD1), since it is well known that the method used here to quantify ROS levels (Nitroblue Tetrazolium assay) is capable of reacting with several types of ROS, but is more sensitive to superoxide anion. Because AT-RvD1 was able to decrease other oxidative stress marker such as catalase activity we can infer that AT-RvD1 had an antioxidant effect in this emphysema model.
In an attempt to understand the signaling pathway in which ATRvD1 acts, it was determined that the mice with emphysema undergo an alteration in the main signaling pathway in responses to oxidative stimuli, namely the Nrf2/Keap1 pathway. The prevalence in the expression of Keap1 on Nrf2 in this group indicates that Nrf2 does not translocate to the nucleus, so the transduction of antioxidant enzymes is not stimulated, as evidenced by the decrease in the expression of HO-1 in the same group. As expected, treatment with AT-RvD1 reversed this situation, upregulated the expression of Nrf2 to the detriment of the expression of Keap1 and the increased expression of HO-1. In an endothelial-mesenchymal transition model using TGF-beta stimulation, HUVEC cells pretreated with AT-RvD1 were shown to restore the expression of Nrf2 that had been inhibited by TGF-beta [49] .
One limitation of this study is that a positive-control treatment for emphysema (e.g. n-acetylcysteine or dexamethasone) was not used to compare its efficacy against the efficacy of AT-RvD1. However, there are no therapeutic drugs for humans that cure emphysema yet; the current drug therapies only attenuate the symptoms. In addition, we acknowledge that we did not quantify the expression of intranuclear Nrf2 to confirm its translocation from the nucleus; however, the increase in the expression of one of the main enzymes produced by its translocation and subsequent transduction (HO-1) supports this hypothesis. Finally, BAL cells and ROS observed here are inconsistent with previous result from our group [50] [51] [52] . However this apparent inconsistency maybe due vehicle/resource route of administration (please see Supplement).
In summary, we have demonstrated that AT-RvD1 has anti-inflammatory, antioxidant and pro-resolutive effects via regulation of the Nrf2/Keap1 pathway in a murine model of emphysema induced by CS, and AT-RvD1 promoted lung tissue repair. This study confirms the importance of lipid mediators in the modulation of emphysema and during resolution of lung remodeling.
Supplementary data to this article can be found online at https:// doi.org/10.1016/j.intimp.2018.01.045.
